Clinicians' recognition of the metabolic adverse effects of antipsychotic medications.
about
Changes in body weight and psychotropic drugs: a systematic synthesis of the literatureGenetics of antipsychotic treatment emergent weight gain in schizophrenia.The appropriateness of routine medication treatment for schizophrenia.Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices.Pharmacological treatment of ambulatory schizophrenic patients in BelgiumPhysical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level.Attitudes toward metabolic adverse events among patients with schizophrenia in Japan.Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study.Metabolic syndrome in people with schizophrenia: a review.Primary care providers' views on metabolic monitoring of outpatients taking antipsychotic medication.Roles in and barriers to metabolic screening for people taking antipsychotic medications: a survey of psychiatrists.Psychiatrists' follow-up of identified metabolic risk: a mixed-method analysis of outcomes and influences on practicePsychiatrists' attitudes toward metabolic adverse events in patients with schizophrenia.Using Routine Hemoglobin A1c Testing to Determine the Glycemic Status in Psychiatric Inpatients.Statistically significant increase in weight caused by low-dose quetiapine.Increased cardiovascular mortality in people with schizophrenia: a 24-year national register study.Reducing cardiovascular risk factors in non-selected outpatients with schizophrenia.Reducing cardiovascular risk factors in non-selected outpatients with schizophrenia.Physical health monitoring in mental health settings: a study exploring mental health nurses' views of their role.Monitoring and management of metabolic abnormalities: mixed-method evaluation of a successful intervention.Side effects of second-generation antipsychotics: the experiences, views and monitoring practices of Australian child psychiatrists.Assessment of cardiovascular disease risk in patients with schizophrenia spectrum disorders in German psychiatric hospitals: results of the pharmacoepidemiologic CATS study.Improving cardiovascular disease screening in community mental health centers.Predictive utility of blood pressure, waist circumference and body mass index for metabolic syndrome in patients with schizophrenia in Singapore.Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone.Recent Swedish clinical practice guidelines for prevention and management of metabolic risk.
P2860
Q28728401-803AD758-5F26-4ABF-B9A1-11308981DD37Q33257886-095B745E-0809-4576-A6E0-D81CAE91F300Q33950877-542496B4-B4DB-43A3-99EC-08DAB8E0B8B0Q34623350-0BB31174-5DDE-45D3-AA5B-F2596190658FQ34631699-27CC64F5-F855-414C-B5DA-AC39823C0FF2Q34691376-36E02AA5-1A30-4D16-870E-C33B993C0F8FQ35016170-CAB3B30F-C98C-4289-AA23-4702B1444498Q36631551-D69FC5C5-85E9-426F-88A8-34AF669C4124Q37095956-0E728261-7E49-4593-92D2-13F600810402Q37129646-20B8FC9C-DFC3-4D31-9869-C2ECAF0D42B9Q37191101-481A5F5E-2C21-4E83-AB42-664EB2DA184FQ37296552-3628E7B1-DE4D-477D-A097-C5A04A12BD10Q37304238-B8F8F392-1598-47A3-94EB-24AD349387D5Q37510663-8C1DF456-DCCC-4BDE-B8AB-75936F79FBCBQ37721692-39A23A49-B2C4-42A2-9A42-3A1C6C4BBEE2Q37793086-C83B456B-FAAF-414E-BD01-C18B635C0946Q38744157-196498AF-31D3-468D-812B-07AB7014A1CBQ38853963-133A8B72-97BB-4EC8-8781-DA4BD6A8E674Q38890884-48558D6C-C38F-4ABF-A319-34DF9E68FDF4Q39164111-81CD8BB6-C8DD-4296-9937-7A3C1BE1B089Q44009250-472F3C8A-3B98-4FD5-B226-F0550B156235Q44387572-07EF27AE-F682-40E1-8506-AC46ADA5B18BQ45632870-8401C167-4B98-4471-B90C-3DE731C6967DQ50702420-6BC5B5EA-5C2B-4397-B77F-59CA81B8CB85Q50751012-2D42F473-39A7-4850-A5F6-F58E05FFF828Q51391762-4889B8CA-C1AC-4452-8B97-B817E2F7F25DQ51838849-72134C00-27EE-4B66-84D7-791E5ECF2F9B
P2860
Clinicians' recognition of the metabolic adverse effects of antipsychotic medications.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Clinicians' recognition of the metabolic adverse effects of antipsychotic medications.
@ast
Clinicians' recognition of the metabolic adverse effects of antipsychotic medications.
@en
type
label
Clinicians' recognition of the metabolic adverse effects of antipsychotic medications.
@ast
Clinicians' recognition of the metabolic adverse effects of antipsychotic medications.
@en
prefLabel
Clinicians' recognition of the metabolic adverse effects of antipsychotic medications.
@ast
Clinicians' recognition of the metabolic adverse effects of antipsychotic medications.
@en
P2093
P1476
Clinicians' recognition of the metabolic adverse effects of antipsychotic medications
@en
P2093
Beth Singer
Edna M Stirewalt
John Arena
Peter F Buckley
P304
P356
10.1016/J.SCHRES.2005.04.010
P407
P50
P577
2005-06-20T00:00:00Z